Business
IGC Pharma Reaches 70% Enrollment in Phase 2 CALMA Trial Evaluating IGC-AD1 for Alzheimer's Agitation
POTOMAC, MARYLAND / ACCESS Newswire / February 2, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), today reported it has reached approximately 70% of planned patient enrollment in its Phase 2 CALMA clinical trial evaluating IGC-AD1 ...
About this update from Igc Pharma, Inc.
[{"type":"text","content":"POTOMAC, MARYLAND / ACCESS Newswire / February 2, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), today reported it has reached approximately 70% of planned patient enrollment in its Phase 2 CALMA clinical trial evaluating IGC-AD1 for the treatment of agitation associated with Alzheimer's disease.","length":344,"tagName":"p"},{"type":"text","content":"The Company has approximately 23 active sites across 26 locations, and enrollment is progressing across this clinical network. IGC expects to complete enrollment by mid-2026. The Company believes this milestone meaningfully reduces the primary operational risk for the trial and positions CALMA to progress toward database lock and topline results.","length":348,"tagName":"p"},{"type":"text","content":""Reaching ~70% enrollment reflects improving execution and site productivity across our network," said Ram Mukunda, CEO of IGC Pharma. "Enrollment is the final operational gate, and our focus is straightforward: complete enrollment efficiently while maintaining data quality and rigorous trial conduct."","length":323,"tagName":"p"},{"type":"text","content":"Operational Updates","length":19,"tagName":"p"},{"type":"text","content":"The Company has continued to activate experienced sites and expand patient access through a hybrid, decentralized model in select geographies. IGC expects enrollment progress to continue as additional site capacity comes online, and newly activated sites ramp to steady-state contribution. In a randomized, double-blind, placebo-controlled study, efficacy outcomes are not analyzed on an ongoing interim basis to preserve blinding and trial integrity.","length":451,"tagName":"p"},{"type":"text","content":"IGC-AD1 is an investigational, cannabinoid-based therapy being evaluated in a randomized, double-blind, placebo-controlled clinical trial designed to assess safety and efficacy in agitation associated with Alzheimer's disease.","length":230,"tagName":"p"},{"type":"text","content":"About IGC Pharma (dba IGC):","length":27,"tagName":"p"},{"type":"text","content":"IGC Pharma (NYSE American: IGC) is a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders. Our lead asset, IGC-AD1, is a cannabinoid-based therapy currently in a P...